Journal of Nephrology & Therapeutics

Alan Weinberg

Publications

• Research Article
  Dose Escalation, Safety and Impact of a Strain-Specific Probiotic (Renadyl™) on Stages III and IV Chronic Kidney Disease Patients
  Author(s): Natarajan Ranganathan, Bohdan Pechenyak, Usha Vyas, Pari Ranganathan, Stephanie DeLoach, Bonita Falkner, Alan Weinberg, Subodh J Saggi and Eli A FriedmanNatarajan Ranganathan, Bohdan Pechenyak, Usha Vyas, Pari Ranganathan, Stephanie DeLoach, Bonita Falkner, Alan Weinberg, Subodh J Saggi and Eli A Friedman
  
  The primary goal of the open label study of Renadyl™ in stage 3 and 4 chronic kidney disease patients was to confirm the safety and tolerability of several doses of Renadyl™ (90, 180, 270 billion colony forming units). Secondary goals were to quantify quality of life improvement, to confirm efficacy in reducing commonly known uremic toxins, and to investigate the effects on several biomarkers of inflammation and oxidative stress. Participants underwent physical examinations and venous blood testing, and completed quality of life questionnaires. Data were analyzed with SAS V9.2. Of 31 subjects, 28 (90%) completed the study (2 lost to follow-up). The primary goal was met, as no significant adverse events were noted during the dose escalation phase. All patients tolerated the maximum dose (note: 1 subject reported nausea upon initial use). The escalation efficacy was shown in.. Read More»
  DOI: 10.4172/2161-0959.1000141

  Abstract PDF